Cipla snatches 1st US manufacturing plant as part of 'landmark acquisition'
- Indian drugmaker Cipla has closed what it's calling a "landmark acquisition" of its first-ever U.S. manufacturing plant, located in Long Island.
- As FiercePharma Manufacturing reports, the acquisition of the manufacturing plant is related to Cipla's purchase of two U.S. drugmakers (NY-based InvaGen Pharma and Georgia-based Exelan Pharmaceuticals).
- InvaGen is a generic drug firm with 62 products either on the market or in-development. Cipla has announced a pretty impressive pipeline of its own, with a reported 200 drugs in development.
"InvaGen's balanced portfolio, robust manufacturing base and strong R&D capabilities will act as lever to expand Cipla's reach in the US market," said Umang Vohra, global chief operating officer of Cipla (EU), in a statement.
Cipla has been driving hard to shore up an organic presence in the North American market. The company is plotting more than a dozen abbreviated drug applications per year, and the acquisition of the two U.S.-based firms and manufacturing plant is a major part of that strategy.
While this is a major catch for Cipla, the firm has also had to deal with regulatory woes with the FDA, as have many other Indian drugmakers.
- FiercePharma Manufacturing Cipla secures first U.S. manufacturing plant
- BioPharma Dive FDA alleges deleted files, hidden data at India's Wockhardt
- BioPharma Dive Cipla's pipeline bursting with more than 200 drugs